Renal Biomarkers Market, By Biomarkers (Kits and reagents, Functional Biomarkers, Upregulated Proteins, and Other Novel Biomarkers), By Diagnostic Method, By End Use, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV5202
|
Published Date
May 2026
|
Pages
353
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Renal Biomarkers Market size was valued at US$ 1,650.83 Million in 2025, expanding at a CAGR of 8.55% from 2026 to 2033.
Renal biomarkers are naturally occurring biological substances found in blood, urine, or kidney tissue that help healthcare professionals assess kidney function. These markers enable early detection of kidney stress, inflammation, or damage before severe complications develop. Traditional indicators such as serum creatinine and estimated glomerular filtration rate (eGFR) remain widely used, while advanced biomarkers including NGAL, KIM-1, and cystatin C are improving the accuracy and sensitivity of kidney disease diagnosis. Their growing clinical importance is driven by the increasing demand for earlier detection, improved patient monitoring, and more personalized treatment approaches in nephrology care.
The use of renal biomarkers is steadily increasing as healthcare systems place greater focus on chronic kidney disease, diabetes-related kidney complications, and acute kidney injury. According to the World Health Organization, kidney diseases are becoming a major contributor to the global disease burden due to rising metabolic and lifestyle-related risk factors. In addition, the International Society of Nephrology reports that millions of people worldwide still lack access to early kidney diagnostic and treatment services, highlighting the need for greater investment in advanced testing technologies and preventive healthcare programs.
Renal Biomarkers Market- Market Dynamics
Increasing burden of chronic kidney diseases driving demand for early diagnostic solutions
The rising number of people affected by chronic kidney disease is increasing demand for renal biomarker-based diagnostic solutions, as early-stage kidney disorders often progress silently without noticeable symptoms. Healthcare providers are therefore placing greater emphasis on diagnostic tools that can detect kidney stress and damage at an early stage, before serious complications develop. According to the International Society of Nephrology, nearly 850 million people worldwide are living with kidney-related diseases, highlighting the growing need for effective screening and monitoring solutions. In addition, the UK Kidney Association reports that chronic kidney disease is becoming a major contributor to long-term healthcare burden due to rising rates of diabetes, hypertension, and aging populations.
Healthcare systems and diagnostic companies are increasingly investing in advanced renal testing technologies to enable earlier intervention and more personalized treatment planning. Companies such as Roche and Abbott Laboratories are expanding their kidney function assessment and biomarker-based diagnostic portfolios to improve disease detection and clinical monitoring capabilities.
Renal Biomarkers Market- Segmentation Analysis:
The Global Renal Biomarkers Market is segmented on the basis of Biomarkers, Diagnostic Method, End Use, and Region.
Within different diagnostic methods, the market is segmented into five categories. Molecular diagnostics is gaining significant attention as it enables the detection of kidney-related molecular alterations at an early stage, even before structural damage becomes clinically evident. This makes it highly valuable for precision-based kidney disease monitoring and informed clinical decision-making. Companies are advancing this segment through continuous innovation in molecular platforms. Thermo Fisher Scientific has expanded its molecular diagnostic solutions, supporting biomarker research and kidney disease testing workflows in clinical laboratories. Similarly, Roche is developing molecular and companion diagnostic technologies that enhance disease detection accuracy and patient monitoring capabilities.
Based on end-use classification, the market is divided into four categories. Among these, diagnostic laboratories play a crucial role as primary testing centers where most kidney function assessments and biomarker analyses are conducted. These laboratories process large volumes of blood and urine samples, enabling early diagnosis, disease monitoring, and follow-up testing for patients with chronic kidney conditions. From an industry perspective, Siemens Healthineers provides advanced laboratory diagnostic and immunoassay systems that support kidney biomarker analysis in clinical settings. Likewise, Danaher Corporation, through its life sciences and diagnostics businesses, supplies laboratory instruments and testing solutions that enhance biomarker-based disease detection and monitoring.
Renal Biomarkers Market- Geographical Insights
From a geographical perspective, the sector is evolving steadily as healthcare systems across regions place increasing emphasis on early kidney disease detection, preventive diagnostics, and advanced patient monitoring technologies. Among regions, North America is expected to register significant growth in the market, driven by rising focus on early kidney disease identification, precision diagnostics, and chronic disease management. The increasing burden of diabetes, hypertension, and aging populations has encouraged hospitals and research institutions to adopt advanced biomarker-based testing to enable earlier intervention and improved patient outcomes. According to the Centers for Disease Control and Prevention, around 37 million American adults are estimated to have chronic kidney disease, while nearly 9 in 10 individuals remain undiagnosed, highlighting the urgent need for improved screening and diagnostic tools.
The National Institute of Diabetes and Digestive and Kidney Diseases also reports that more than 808,000 people in the United States are living with end-stage kidney disease, requiring dialysis or transplantation support. In addition, CDC surveillance programs continue to support biomarker-focused kidney research initiatives aimed at improving early disease prediction and treatment planning. From an industry perspective, Quest Diagnostics is expanding renal testing capabilities through specialized laboratory services, supporting broader clinical adoption of kidney biomarker diagnostics across the healthcare system.
China Renal Biomarkers Market- Country Insights
China is witnessing increasing attention toward renal biomarkers as healthcare authorities and medical institutions place greater focus on early kidney disease screening and chronic disease management. Rising prevalence of diabetes, hypertension, and an aging population is encouraging hospitals to adopt advanced diagnostic approaches capable of identifying kidney damage at earlier stages. According to the Chinese Center for Disease Control and Prevention and the Sixth China Chronic Disease and Risk Factor Surveillance, nearly 82 million adults in China are living with chronic kidney disease, highlighting a significant need for improved renal monitoring tools.
In addition, a national assessment linked with the Global Burden of Disease Study reports that China accounts for more than 156 million chronic kidney disease cases, reflecting increasing pressure on healthcare infrastructure and diagnostic systems. From an industry perspective, Fosun Pharma is expanding its diagnostics and biotechnology activities, supporting the development of precision testing solutions and biomarker-based healthcare applications across China’s medical sector.
Renal Biomarkers Market- Competitive Landscape:
Supported by the development of early disease detection programs and rising awareness of chronic kidney disorders, the renal biomarkers sector is witnessing steady growth driven by diagnostic companies, biotechnology firms, and healthcare technology providers. Major players such as F. Hoffmann-La Roche, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, and Danaher Corporation are focusing on improving diagnostic accuracy, automation capabilities, and laboratory efficiency to enhance kidney disease detection and management. Companies are increasingly expanding their portfolios, investing in biomarker validation studies, and strengthening collaborations with hospitals and laboratories to improve access to renal testing solutions. For instance, Quanterix Corporation completed the acquisition of Akoya Biosciences to expand biomarker analysis capabilities across blood and tissue-based applications. Similarly, Quest Diagnostics enhanced its renal testing capabilities through the acquisition of selected clinical laboratory assets from Fresenius Medical Care’s Spectra Laboratories.
Recent Developments
- In October 2025, XORTX Therapeutics agreed to acquire Vectus Biosystems’ renal anti-fibrotic therapeutic program, including the VB4-P5 compound designed for progressive kidney disease management and future biomarker-linked applications. This acquisition strengthens its renal disease portfolio and supports biomarker-driven therapeutic development.
- In April 2025, Novartis announced the acquisition of Regulus Therapeutics to strengthen its renal disease pipeline through farabursen, an investigational microRNA inhibitor for autosomal dominant polycystic kidney disease (ADPKD), a major genetic cause of kidney failure. This deal enhances innovation in renal therapeutics and supports biomarker-driven kidney disease research globally.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RENAL BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Abbott Laboratories
- F. Hoffmann-La Roche AG
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
- bioMérieux SA
- Beckman Coulter (Danaher Corporation)
- Bio-Rad Laboratories Inc.
- Randox Laboratories Ltd.
- SEKISUI Medical Co., Ltd.
- DiaSorin S.p.A.
- QIAGEN N.V.
- Becton, Dickinson and Company (BD)
- PerkinElmer Inc.
- Enzo Biochem Inc.
- SphingoTec GmbH
- EKF Diagnostics Holdings plc
- Quanterix Corporation
- Novartis
- Merck KGaA
- Tosoh Bioscience
- XORTX Therapeutics
- Others
GLOBAL RENAL BIOMARKERS MARKET, BY BIOMARKERS- MARKET ANALYSIS, 2020 - 2033
- Kits and reagents
- Functional Biomarkers
- Serum Creatinine
- Blood Urea Nitrogen (BUN)
- Estimated Glomerular Filtration Rate (eGFR)
- Upregulated Proteins
- Kidney Injury Molecule-1 (KIM-1)
- Neutrophil Gelatinase-Associated Lipocalin (NGAL)
- Cystatin C
- Interleukin-18 (IL-18)
- Others
- Other Novel Biomarkers
- microRNA biomarkers
- Proteomic/metabolomic markers
- Others
GLOBAL RENAL BIOMARKERS MARKET, BY DIAGNOSTIC METHOD- MARKET ANALYSIS, 2020 - 2033
- Immunoassays
- Clinical Chemistry Assays
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Molecular Diagnostic
- Point-of-Care Testing (POCT) Devices
- Others
GLOBAL RENAL BIOMARKERS MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033
- Diagnostic Laboratories
- Hospitals & Clinics
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
GLOBAL RENAL BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Renal Biomarkers Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Renal Biomarkers Market Snippet by Biomarkers
2.1.2. Renal Biomarkers Market Snippet by Diagnostic Method
2.1.3. Renal Biomarkers Market Snippet by End Use
2.1.4. Renal Biomarkers Market Snippet by Country
2.1.5. Renal Biomarkers Market Snippet by Region
2.2. Competitive Insights
3. Renal Biomarkers Key Market Trends
3.1. Renal Biomarkers Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Renal Biomarkers Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Renal Biomarkers Market Opportunities
3.4. Renal Biomarkers Market Future Trends
4. Renal Biomarkers Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Renal Biomarkers Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Renal Biomarkers Market Landscape
6.1. Renal Biomarkers Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Renal Biomarkers Market – By Biomarkers
7.1. Overview
7.1.1. Segment Share Analysis, By Biomarkers, 2025 & 2033 (%)
7.1.2. Kits and reagents
7.1.3. Functional Biomarkers
7.1.3.1. Serum Creatinine
7.1.3.2. BUN
7.1.3.3. eGFR
7.1.4. Upregulated Proteins
7.1.4.1. KIM-1
7.1.4.2. NGAL
7.1.4.3. Cystatin C
7.1.4.4. IL-18
7.1.4.5. Others
7.1.5. Other Novel Biomarkers
7.1.5.1. microRNA biomarkers
7.1.5.2. Proteomic/metabolomic markers
7.1.6. Others
8. Renal Biomarkers Market – By Diagnostic Method
8.1. Overview
8.1.1. Segment Share Analysis, By Diagnostic Method, 2025 & 2033 (%)
8.1.2. Immunoassays
8.1.3. Clinical Chemistry Assays
8.1.4. Enzyme-Linked Immunosorbent Assay (ELISA)
8.1.5. Molecular Diagnostic
8.1.6. Point-of-Care Testing (POCT) Devices
8.1.7. Others
9. Renal Biomarkers Market – By End Use
9.1. Overview
9.1.1. Segment Share Analysis, By End Use, 2025 & 2033 (%)
9.1.2. Diagnostic Laboratories
9.1.3. Hospitals & Clinics
9.1.4. Academic & Research Institutes
9.1.5. Pharmaceutical & Biotechnology Companies
9.1.6. Others
10. Renal Biomarkers Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
10.2. North America
10.2.1. Overview
10.2.2. Renal Biomarkers Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.2.4. North America Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.2.5. North America Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.2.6. North America Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Renal Biomarkers Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.6. Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.9.5. France Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.16. Denmark
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.16.3. Denmark Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.16.4. Denmark Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.16.5. Denmark Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.17. Rest of Europe
10.3.17.1. Overview
10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.17.3. Rest of the Europe Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.3.17.4. Rest of the Europe Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.3.17.5. Rest of the Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Renal Biomarkers Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.6. APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.7.5. China Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.8.5. India Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.15. Taiwan
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.15.3. Taiwan Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.15.4. Taiwan Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.15.5. Taiwan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.16. Vietnam
10.4.16.1. Overview
10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.16.3. Vietnam Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.16.4. Vietnam Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.16.5. Vietnam Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.17. Rest of APAC
10.4.17.1. Overview
10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.17.3. Rest of APAC Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.4.17.4. Rest of APAC Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.4.17.5. Rest of APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Renal Biomarkers Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Renal Biomarkers Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.6.6. MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.13. Iran
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.13.3. Iran Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.6.13.4. Iran Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.6.13.5. Iran Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.14. Qatar
10.6.14.1. Overview
10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.14.3. Qatar Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.6.14.4. Qatar Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.6.14.5. Qatar Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.15. Rest of MEA
10.6.15.1. Overview
10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.15.3. Rest of MEA Market Size and Forecast, By Biomarkers, 2020 - 2033 (US$ Million)
10.6.15.4. Rest of MEA Market Size and Forecast, By Diagnostic Method, 2020 - 2033 (US$ Million)
10.6.15.5. Rest of MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11. Key Vendor Analysis- Renal Biomarkers Industry
11.1. Competitive Benchmarking
11.1.1. Competitive Dashboard
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. Abbott Laboratories
11.2.2. F. Hoffmann-La Roche AG
11.2.3. Siemens Healthineers
11.2.4. Thermo Fisher Scientific Inc.
11.2.5. bioMérieux SA
11.2.6. Beckman Coulter (Danaher Corporation)
11.2.7. Bio-Rad Laboratories Inc.
11.2.8. Randox Laboratories Ltd.
11.2.9. SEKISUI Medical Co., Ltd.
11.2.10. DiaSorin S.p.A.
11.2.11. QIAGEN N.V.
11.2.12. Becton, Dickinson and Company (BD)
11.2.13. PerkinElmer Inc.
11.2.14. Enzo Biochem Inc.
11.2.15. SphingoTec GmbH
11.2.16. EKF Diagnostics Holdings plc
11.2.17. Quanterix Corporation
11.2.18. Novartis
11.2.19. Merck KGaA
11.2.20. Tosoh Bioscience
11.2.21. XORTX Therapeutics
11.2.22. Others
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RENAL BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Abbott Laboratories
- F. Hoffmann-La Roche AG
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
- bioMérieux SA
- Beckman Coulter (Danaher Corporation)
- Bio-Rad Laboratories Inc.
- Randox Laboratories Ltd.
- SEKISUI Medical Co., Ltd.
- DiaSorin S.p.A.
- QIAGEN N.V.
- Becton, Dickinson and Company (BD)
- PerkinElmer Inc.
- Enzo Biochem Inc.
- SphingoTec GmbH
- EKF Diagnostics Holdings plc
- Quanterix Corporation
- Novartis
- Merck KGaA
- Tosoh Bioscience
- XORTX Therapeutics
- Others
GLOBAL RENAL BIOMARKERS MARKET, BY BIOMARKERS- MARKET ANALYSIS, 2020 - 2033
- Kits and reagents
- Functional Biomarkers
- Serum Creatinine
- Blood Urea Nitrogen (BUN)
- Estimated Glomerular Filtration Rate (eGFR)
- Upregulated Proteins
- Kidney Injury Molecule-1 (KIM-1)
- Neutrophil Gelatinase-Associated Lipocalin (NGAL)
- Cystatin C
- Interleukin-18 (IL-18)
- Others
- Other Novel Biomarkers
- microRNA biomarkers
- Proteomic/metabolomic markers
- Others
GLOBAL RENAL BIOMARKERS MARKET, BY DIAGNOSTIC METHOD- MARKET ANALYSIS, 2020 - 2033
- Immunoassays
- Clinical Chemistry Assays
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Molecular Diagnostic
- Point-of-Care Testing (POCT) Devices
- Others
GLOBAL RENAL BIOMARKERS MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033
- Diagnostic Laboratories
- Hospitals & Clinics
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
GLOBAL RENAL BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
